Ab-initio pharma | Formulation and GMP product manufacturing services for clinical trials in Australia
Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.
The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.
Outcomes (FY2020):
- Facility has been designed
- The build is beginning and installation of machinery planned for FY2021.
Visit The University of Sydney & Ab-Initio-Pharma for more information.
Twitter: Sydney_Uni & @AbinitioPharma
LinkedIn: The University of Sydney & Ab Initio Pharma
| Consortium Lead | The University of Sydney |
| Consortium Members | Ab Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia |
| MTPConnect Grant | $500,000 |
| Industry Contribution | $716,000 |
| State Government Contribution | $200,000 |
| Project Duration | June 2018 - October 2021 |
| Contact | Paul Young, Ab Initio - paul.young@ab-initio-pharma.com |